US gives conditional nod to Zoetis' bird flu vaccine for poultry

Reuters
02-15
UPDATE 3-US gives conditional nod to Zoetis' bird flu vaccine for poultry

Adds details on the Wyoming case in paragraph 3

Feb 14 (Reuters) - The U.S. Department of Agriculture has given a conditional approval to Zoetis ZTS.N to use its bird flu vaccine in poultry, the animal healthcare company said on Friday.

Bird flu has infected nearly 70 people in the United States, with one death, since last April. Most of those infections have been among farm workers exposed to infected poultry or cows.

The Wyoming Department of Health said on Friday it has identified its first human case of H5N1 bird flu in the region, making it the third confirmed instance of hospitalization related to the infection in the United States.

The U.S. Centers for Disease Control and Prevention, however, has said the risk to the general public from bird flu is low.

Zoetis, which deals with vaccines, medicines as well as diagnostic solutions for animals, said the conditional license was granted based on safety and reasonable expectation of efficacy.

A conditional approval, called a conditional license, is used for emergencies, limited market availability, or other special circumstance and is issued for a finite period of time.

Last month, USDA said it would rebuild a stockpile of bird flu vaccines for poultry that match the strain of the virus circulating in commercial flocks and wild birds.

The U.S. had built a poultry vaccine stockpile after major bird flu outbreaks in 2014 and 2015, though they were never used.

The vaccines were developed by Merck MRK.N, Ceva CEVA.O and one by U.S. government researchers, David Suarez, who was acting laboratory director of USDA's Southeast Poultry Research Laboratory in Athens, Georgia, had said in a 2023 interview.

Separately, Moderna MRNA.O is developing a bird flu vaccine for humans and has received about $766 million from the U.S. government for its advancement.

The company said last month it was preparing to advance its experimental shot, mRNA-1018, into late-stage trials based on preliminary data from an early- to mid-stage study.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)

((Christy.Santhosh@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10